SEARCH

SEARCH BY CITATION

References

  • Abbas T., Faivre E. and Holscher C. (2009) Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205, 265271.
  • Akter K., Lanza E. A., Martin S. A., Myronyuk N., Rua M. and Raffa R. B. (2011) Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br. J. Clin. Pharmacol. 71, 365376.
  • Campbell R. K. and Miller S.. (2009) New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy. Diabetes Educ. 35, 731747.
  • Cao F., Hata R., Zhu P., Nakashiro K. and Sakanaka M. (2010) Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells. Biochem. Biophys. Res. Commun. 394, 843847.
  • Chen B. and Cepko C. L. (2009) HDAC4 regulates neuronal survival in normal and diseased retinas. Science 323, 256259.
  • Dickson S. L., Shirazi R. H., Hansson C., Bergquist F., Nissbrandt H. and Skibicka K. P. (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 32, 48124820.
  • Drucker D. J. (2006) The biology of incretin hormones. Cell Metab. 3, 153165.
  • Frank D. A. and Greenberg M. E. (1994) CREB: a mediator of long-term memory from mollusks to mammals. Cell 79, 58.
  • Gengler S., McClean P. L., McCurtin R., Gault V. A. and Holscher C. (2010) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 265276.
  • Gilman C. P., Perry T., Furukawa K., Grieg N. H., Egan J. M. and Mattson M. P. (2003) Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem. 87, 11371144.
  • Graham R. K., Ehrnhoefer D. E. and Hayden M. R. (2011) Caspase-6 and neurodegeneration. Trends Neurosci. 34, 646656.
  • Hamilton A., Patterson S., Porter D., Gault V. A. and Holscher C. (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481489.
  • Han W. and Li C. (2010) Linking type 2 diabetes and Alzheimer's disease. Proc. Natl Acad. Sci. USA 107, 65576558.
  • Hardy J. (2006) A hundred years of Alzheimer's disease research. Neuron 52, 313.
  • Ho L., Qin W., Pompl P. N. et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18, 902904.
  • Holscher C. and Li L. (2010) New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol. Aging 31, 14951502.
  • Ioacara S., Guja C., Ionescu-Tirgoviste C., Fica S., Sabau S., Radu S., Micu A. and Tiu C. (2011) Improvements in life expectancy in adult type 2 diabetes patients in the last six decades. Diabetes Res. Clin. Pract. 92, 400404.
  • Irwin N., Gault V. and Flatt P. R. (2010) Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin. Investig. Drugs 19, 10391048.
  • Jack C. R. Jr, Knopman D. S., Jagust W. J., Shaw L. M., Aisen P. S., Weiner M. W., Petersen R. C. and Trojanowski J. Q. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119128.
  • Kallur T., Gisler R., Lindvall O. and Kokaia Z. (2008) Pax6 promotes neurogenesis in human neural stem cells. Mol. Cell. Neurosci. 38, 616628.
  • Li Y., Tweedie D., Mattson M. P., Holloway H. W. and Greig N. H. (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113, 16211631.
  • McClean P. L., Parthsarathy V., Faivre E. and Holscher C. (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 65876594.
  • Migani P., Bartlett C., Dunlop S., Beazley L. and Rodger J. (2009) Regional and cellular distribution of ephrin-B1 in adult mouse brain. Brain Res. 1247, 5061.
  • Nikolic M., Dudek H., Kwon Y. T., Ramos Y. F. and Tsai L. H. (1996) The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816825.
  • Ott A., Stolk R., Harskamp F. V., Pols H., Hoffman A. and Breteler M. (1999) Diabetes mellitus and the risk of dementia. The Rotterdam study. Neurology 53, 19371942.
  • Palmer A. M. (2011) Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci. 32, 141147.
  • Perry T. and Greig N. H. (2002) The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 4, 487496.
  • Perry T. and Greig N. H. (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377385.
  • Phillips H. S., Hains J. M., Armanini M., Laramee G. R., Johnson S. A. and Winslow J. W. (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695702.
  • Pruunsild P., Sepp M., Orav E., Koppel I. and Timmusk T. (2011) Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J. Neurosci. 31, 32953308.
  • Pugazhenthi S., Boras T., O'Connor D., Meintzer M. K., Heidenreich K. A. and Reusch J. E. (1999a) Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells. Involvement of p38 mitogen-activated protein kinase-mediated pathway. J. Biol. Chem. 274, 28292837.
  • Pugazhenthi S., Miller E., Sable C., Young P., Heidenreich K. A., Boxer L. M. and Reusch J. E.-B. (1999b) Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element binding protein. J. Biol. Chem. 274, 2752927535.
  • Pugazhenthi S., Nesterova A., Sable C., Heidenreich K., Boxer L., Heasley L. and Reusch J. (2000) Akt/Protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275, 1076110766.
  • Pugazhenthi S., Nesterova A., Jambal P., Audesirk G., Kern M., Cabell L., Eves E., Rosner M. R., Boxer L. M. and Reusch J. E. (2003) Oxidative stress-mediated down-regulation of bcl-2 promoter in hippocampal neurons. J. Neurochem. 84, 982996.
  • Pugazhenthi S., Phansalkar K., Audesirk G., West A. and Cabell L. (2006) Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic. Biol. Med. 40, 2134.
  • Pugazhenthi U., Velmurugan K., Tran A., Mahaffey G. and Pugazhenthi S. (2010) Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia 53, 23572368.
  • Pugazhenthi S., Wang M., Pham S., Sze C. I. and Eckman C. B. (2011a) Downregulation of CREB expression in Alzheimer's brain and in Abeta-treated rat hippocampal neurons. Mol. Neurodegener. 6, 60.
  • Pugazhenthi S., Nair S., Velmurugan K., Liang Q., Mahalingam R., Cohrs R. J., Nagel M. A. and Gilden D. (2011b) Varicella-zoster virus infection of differentiated human neural stem cells. J. Virol. 85, 66786686.
  • Querfurth H. W. and LaFerla F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329344.
  • Rissman R. A., Poon W. W., Blurton-Jones M., Oddo S., Torp R., Vitek M. P., LaFerla F. M., Rohn T. T. and Cotman C. W. (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121130.
  • Rohn T. T., Vyas V., Hernandez-Estrada T., Nichol K. E., Christie L. A. and Head E. (2008) Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J. Neurosci. 28, 30513059.
  • Roth K. A. (2001) Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J. Neuropathol. Exp. Neurol. 60, 829838.
  • Ryan D. A., Narrow W. C., Federoff H. J. and Bowers W. J. (2010) An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J. Neurosci. Methods 190, 171179.
  • Sarkar S. A., Gunter J., Bouchard R., Reusch J. E., Wiseman A., Gill R. G., Hutton J. C. and Pugazhenthi S. (2007) Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 50, 16491659.
  • Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H. and Morishita R. (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl Acad. Sci. USA 107, 70367041.
  • Valente T., Gella A., Fernandez-Busquets X., Unzeta M. and Durany N. (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol. Dis. 37, 6776.
  • Velmurugan K., Balamurugan A. N., Loganathan G., Ahmad A., Hering B. J. and Pugazhenthi S. (2012) Antiapoptotic Actions of Exendin-4 against Hypoxia and Cytokines Are Augmented by CREB. Endocrinology 11161128.
  • Yamamoto-sasaki M., Ozawa H., Saito T., Rosler M. and Riederer P. (1999) Impaired phosphrylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimers type. Brain Res. 824, 300303.